TD Cowen ASCO 2026 Planner

Research evidence excerpt

TD Cowen ASCO 2026 Planner

TD SECURITIES (USA) LLC SECTOR NOTE

May 21, 2026

■Biotechnology TD Cowen ASCO 2026 Planner

TD Cowen Biotechnology Team THE TD COWEN INSIGHT

646 562 1010

The TD Cowen research team will be in attendance at the ASCO 2026 annual meeting and has

biotechteam@tdsecurities.com

assembled a list of titles relevant to companies under coverage. The ASCO planner provides a

TD Cowen Pharmaceutical Team curated schedule for the full conference, which spans from Friday, May 29th, to Tuesday, June

pharmateam@tdsecurities.com 2nd.

Tyler Van Buren

646 562 1343 The comprehensive 13-page planner is attached. Feel free to request the Excel file from your

tyler.vanburen@tdsecurities.com sales representative.

Tara Bancroft, Ph.D.

646 562 1410 Friday (5/29):

tara.bancroft@tdsecurities.com ■2:12 PM CT in Hall D2 (#8503, NUVL): ALKOVE-1: Efficacy and safety of neladalkib in

Yaron Werber, M.D. patients with advanced ALK+ NSCLC.

646 562 1415

■3:09 PM CT in S100a (#7502, REGN): First results from the phase 1/2 LINKER-AL2 trial of

yaron.werber@tdsecurities.com

linvoseltamab (LINVO) in patients (pts) with relapsed or refractory (RR) systemic light chain

Marc Frahm, Ph.D. (AL) amyloidosis.

646 562 1394

marc.frahm@tdsecurities.com ■4:45 PM CT in S100a (#LBA7506, BMS): Mezigdomide, carfilzomib, and dexamethasone

(MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma

Steve Scala, R.Ph., CFA (RRMM): Results from the Phase 3 SUCCESSOR-2 trial.

617 946 3923

stephen.scala@tdsecurities.com ■6:30 PM CT: Breast Cancer & Melanoma KOL Dinner Hosted By TD Cowen

Michael Nedelcovych, Ph.D.

Saturday (5/30):

617 946 3744

michael.nedelcovych@tdsecurities.com ■8:00 AM CT in E450a (#5509, IMTX): Phase 1a study results for IMA203CD8, a PRAME-